RASP (Actavia Life Sciences) Research & Development: $0.09 Mil (TTM As of Mar. 2024)


What is Actavia Life Sciences Research & Development?

Actavia Life Sciences RASP -87.50% Research & Development is $0.09 Mil as of Mar. 2024.

Research & Development is the aggregate amount of research and development expenses during the year. Actavia Life Sciences's Research & Development for the three months ended in Mar. 2024 was $0.01 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was $0.09 Mil.

Actavia Life Sciences  (OTCPK:RASP) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Actavia Life Sciences Research & Development Related Terms

Actavia Life Sciences Research & Development Historical Data

* Premium members only.

The historical data trend for Actavia Life Sciences's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actavia Life Sciences Research & Development Chart

Actavia Life Sciences Annual Data
Trend Jun14 Jun15 Jun16 Mar17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.00 0.06 0.08 0.09

Actavia Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.05 0.01 0.02 0.01

Actavia Life Sciences Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.09 Mil mean?
Actavia Life Sciences (RASP) has a Research & Development of $0.09 Mil as of Mar. 2024. Research and development expense is the total cost for research and development activities. View historical data on Actavia Life Sciences and its competitors.
Is Actavia Life Sciences' Research & Development too high?
Actavia Life Sciences' current Research & Development is $0.09 Mil.
How does Actavia Life Sciences' Research & Development compare to BWV and FNCH?
Actavia Life Sciences' Research & Development of $0.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Actavia Life Sciences and its competitors. Actavia Life Sciences's current Research & Development is $0.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actavia Life Sciences stock overvalued right now?
Actavia Life Sciences (RASP) has a current Research & Development of $0.09 Mil. The current Research & Development is $0.09 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Actavia Life Sciences (RASP), the current Research & Development is $0.09 Mil as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actavia Life Sciences Business Description

Address 5 Penn Plaza, No.1954, 19th Floor, New York, NY, USA, 10001
Actavia Life Sciences Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.